Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapies. N = 62 clinical trials (Phase I, II, or I/II) evaluating the infusion of non-engineered allogeneic NK cells in combination with other agents were registered on ClinicalTrials.gov until 31–12–2021. Studies are sorted by types of combination therapy (NK cell priming agents, Adoptive cell therapy, Antibodies, Co-stimulation, Multiple combinations, Molecular inhibitors and NK cell engagers). Details of the combination approach and the clinical trial design and outcome (when available) are presented. Trial status is updated to August 2022